Skip to main content
Erschienen in: Antimicrobial Resistance & Infection Control 1/2015

Open Access 01.12.2015 | Poster presentation

Understanding barriers to the provision of hand hygiene products in Africa – a WHO POPS/APPS project

verfasst von: J Storr, C Kilpatrick, S Syed, J Dixon Hightower, D Pittet, Private Organizations for Patient Safety

Erschienen in: Antimicrobial Resistance & Infection Control | Sonderheft 1/2015

download
DOWNLOAD
print
DRUCKEN
insite
SUCHEN

Introduction

The availability of alcohol-based handrub (ABHR) and its component parts to enable reliable use in health care are variable around the globe.
Three initiatives from the World Health Organisation (WHO) have addressed this inequity. The WHO guidelines on hand hygiene (2009) promote the use of ABHR as an easy and effective way to ensure clean safe hands at the point of care. WHO Private Organisations for Patient Safety (POPS) harnesses industry strengths to align and improve implementation of WHO recommendations, to hand hygiene in the first instance. WHO African Partnerships for Patient Safety (APPS) focuses on supporting safer healthcare delivery in hospitals with hand hygiene as a linchpin for safe quality care.
In 2013, a one-off project was launched through POPS to provide empty bottles to APPS hospitals so that operational barriers to implementation of locally produced ABHR could be addressed.

Objectives

1. To describe an implementation-focused project spanning three WHO programs responding to locally identified barriers
2. To describe the process involved in providing a short-term solution to the identified problem
3. To systematically identify barriers and recommendations to the problem

Methods

A tripartite approach was employed involving an open call to POPS companies, a targeted call to APPS hospitals that had previously completed a WHO training program on local production of ABHR, and brokering of the interaction between POPS and APPS via the WHO APPS team. A preparation, logistics and communications plan was adopted.

Results

One company provided 27 990 bottles to 6 hospitals in 5 countries in Africa. It took 6 months from the start of the project until final delivery of all hardware to the hospitals. Key challenges related to mode of transportation, barriers to entry, storage and identification of reliable routes from port to hospital. Acknowledgement was received by hospital managers regarding the impact on ABHR availability at point of care.

Conclusion

This project allowed the logistics process to be scrutinized and lessons are informing the next stage of work to address barriers. Availability of ABHR and other required resources in the African region continues to be constrained and action to address this inequity remains a key priority for WHO and POPS informed by this project.

Disclosure of interest

None declared.
This article is published under license to BioMed Central Ltd. This is an Open Access article distributed under the terms of the Creative Commons Attribution License (http://​creativecommons.​org/​licenses/​by/​4.​0), which permits unrestricted use, distribution, and reproduction in any medium, provided the original work is properly cited. The Creative Commons Public Domain Dedication waiver (http://​creativecommons.​org/​publicdomain/​zero/​1.​0/​) applies to the data made available in this article, unless otherwise stated.
Metadaten
Titel
Understanding barriers to the provision of hand hygiene products in Africa – a WHO POPS/APPS project
verfasst von
J Storr
C Kilpatrick
S Syed
J Dixon Hightower
D Pittet
Private Organizations for Patient Safety
Publikationsdatum
01.12.2015
Verlag
BioMed Central
DOI
https://doi.org/10.1186/2047-2994-4-S1-P250

Weitere Artikel der Sonderheft 1/2015

Antimicrobial Resistance & Infection Control 1/2015 Zur Ausgabe

Leitlinien kompakt für die Innere Medizin

Mit medbee Pocketcards sicher entscheiden.

Seit 2022 gehört die medbee GmbH zum Springer Medizin Verlag

Mehr Lebenszeit mit Abemaciclib bei fortgeschrittenem Brustkrebs?

24.05.2024 Mammakarzinom Nachrichten

In der MONARCHE-3-Studie lebten Frauen mit fortgeschrittenem Hormonrezeptor-positivem, HER2-negativem Brustkrebs länger, wenn sie zusätzlich zu einem nicht steroidalen Aromatasehemmer mit Abemaciclib behandelt wurden; allerdings verfehlte der numerische Zugewinn die statistische Signifikanz.

ADT zur Radiatio nach Prostatektomie: Wenn, dann wohl länger

24.05.2024 Prostatakarzinom Nachrichten

Welchen Nutzen es trägt, wenn die Strahlentherapie nach radikaler Prostatektomie um eine Androgendeprivation ergänzt wird, hat die RADICALS-HD-Studie untersucht. Nun liegen die Ergebnisse vor. Sie sprechen für länger dauernden Hormonentzug.

„Überwältigende“ Evidenz für Tripeltherapie beim metastasierten Prostata-Ca.

22.05.2024 Prostatakarzinom Nachrichten

Patienten mit metastasiertem hormonsensitivem Prostatakarzinom sollten nicht mehr mit einer alleinigen Androgendeprivationstherapie (ADT) behandelt werden, mahnt ein US-Team nach Sichtung der aktuellen Datenlage. Mit einer Tripeltherapie haben die Betroffenen offenbar die besten Überlebenschancen.

So sicher sind Tattoos: Neue Daten zur Risikobewertung

22.05.2024 Melanom Nachrichten

Das größte medizinische Problem bei Tattoos bleiben allergische Reaktionen. Melanome werden dadurch offensichtlich nicht gefördert, die Farbpigmente könnten aber andere Tumoren begünstigen.

Update Innere Medizin

Bestellen Sie unseren Fach-Newsletter und bleiben Sie gut informiert.